Forecasted to grow from USD 5.2 billion in 2023 to USD 7.6 billion by 2028, the Blood Culture Tests Market growth is set at a CAGR of 8.0%. Factors contributing to this growth include a high prevalence of infectious diseases, increasing cases of sepsis, and the need for rapid diagnostics. However, challenges such as the shortage of skilled technicians and the high cost of automated equipment may restrict further expansion.
The prominent players in this market are Iridica (US), Biosystems, Inc. (US), BINDER GmBH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio (England), Anaerobe Systems, Inc. (US), Himedia Laboratories Pvt. Ltd. (India), Autobio Diagnostics Co., Ltd. (China), Axiom Laboratories (India), Mikroscan Technologies, Inc. (US), Labotronics Ltd. (UK), Hardy Diagnostics (US), Opgen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Terumo Corporation (Japan), Becton, Dickinson and Company (US), BioMérieux (France), Thermo Fisher Scientific Inc. (US), Danaher (US), Luminex Corporation (US), Bruker (US) and Roche Diagnostics (Switzerland).
Based on method, the blood culture tests market is segmented into conventional/manual blood culture and automated blood culture methods. The conventional/manual blood culture methods segment accounted for the largest share of of the global blood culture tests market. The large share of this segment can be attributed to ease of using conventional systems. Also, conventional systems do not require the purchase of expensive instruments.
Based on products, the market for blood culture tests is primarily divided into consumables, instruments, and software and services. Due to the repeated purchase of media for the detection of bacteria, fungi, and yeast, the consumables segment captures the largest share and is also the fastest growing.
Based on technology, culture-based technologies, molecular technologies, and proteomics make up the major segments of the blood culture tests market. The molecular technologies segment accounted for the high growth in the global blood culture tests market. This can be attributed to the increasing incidence of sepsis, which demands rapid diagnostic techniques for detecting the presence of bacteria, fungi, and mycobacteria from blood samples.
Based on application, the market for blood culture tests is divided into bacteremia, fungemia, and mycobacterial detection. Bacteremia segment is accounted for the largest as well as the highest growing share in the blood culture tests market. This is due to the increasing number of bloodstream infections and the growing number of sepsis cases worldwide.
Based on end users, the blood culture tests market is bifurcated into hospital laboratories, reference laboratories, academic research laboratories, and other laboratories (includes pathology laboratories, bacteriological laboratories, physician office laboratories (POLs), and independent research laboratories). The reference laboratories segment is expected to grow at the highest rate in this market. The high growth of this segment is due to the increasing outsourcing of blood culture tests by hospitals to reference laboratories.
The blood culture tests market is segmented into four major regions–North America, Europe, the Asia Pacific (APAC), and the Middle East & Africa. North America has accounted for the largest market share. Factors such as the increasing incidence of bloodstream infections, high prevalence of infectious diseases, rapidly rising geriatric population, the significant presence of blood culture test providers, and growing product approvals are driving the growth of the market in North America.
Sources:
https://www.marketsandmarkets.com/ResearchInsight/blood-culture-test-market-size-share.asp
https://www.marketsandmarkets.com/PressReleases/blood-culture-test.asp